Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies
Status:
Completed
Trial end date:
2021-03-16
Target enrollment:
Participant gender:
Summary
This study will be conducted to assess the safety and tolerability of BOS172722 when
administered as monotherapy and in combination with paclitaxel in participants with advanced
nonhaematologic malignancies and also to establish the maximum tolerated dose and recommended
Phase 2 dose of BOS172722 in combination with paclitaxel in those participants.